ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Semaglutide Forum: Game Changer for Weight Loss
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 255685" data-attributes="member: 3"><p><strong>Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk</strong></p><p>Wei-Syun Hu a b, Cheng-Li Lin c</p><p></p><p>[URL unfurl="true"]https://doi.org/10.1016/j.jdiacomp.2023.108468[/URL]</p><p></p><p>Highlights</p><p>•The study compared the incidence of cancer between patients with diabetes with and without SGLT2 inhibitors use in Taiwan between 2016-2019.</p><p></p><p>•The strength of this study was from a large dataset.</p><p></p><p>•Out study showed that patients with diabetes who took SGLT2 inhibitors had a significantly lower risk of cancer.</p><p></p><p></p><p>Abstract</p><p>Purpose</p><p>The study compared the incidence of cancer between patients with diabetes with and without sodium-glucose cotransporter-2 (SGLT2) inhibitors use.</p><p></p><p>Methods</p><p>This study identified a non-SGLT2 inhibitor cohort of 325,989 patients and a SGLT2 inhibitor cohort of 325,990 patients. The primary interest of this study was the occurrence of cancer. Hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional hazard models.</p><p></p><p>Results</p><p>Patients receiving SGLT2 inhibitors (adjusted HR = 0.79, 95 % CI = 0.76–0.83) had a significantly lower risk of developing cancer than patients without receiving SGLT2 inhibitors.</p><p></p><p>Conclusion</p><p>The results demonstrated that patients with diabetes receiving SGLT2 inhibitors had a significantly lower risk of cancer.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 255685, member: 3"] [B]Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk[/B] Wei-Syun Hu a b, Cheng-Li Lin c [URL unfurl="true"]https://doi.org/10.1016/j.jdiacomp.2023.108468[/URL] Highlights •The study compared the incidence of cancer between patients with diabetes with and without SGLT2 inhibitors use in Taiwan between 2016-2019. •The strength of this study was from a large dataset. •Out study showed that patients with diabetes who took SGLT2 inhibitors had a significantly lower risk of cancer. Abstract Purpose The study compared the incidence of cancer between patients with diabetes with and without sodium-glucose cotransporter-2 (SGLT2) inhibitors use. Methods This study identified a non-SGLT2 inhibitor cohort of 325,989 patients and a SGLT2 inhibitor cohort of 325,990 patients. The primary interest of this study was the occurrence of cancer. Hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional hazard models. Results Patients receiving SGLT2 inhibitors (adjusted HR = 0.79, 95 % CI = 0.76–0.83) had a significantly lower risk of developing cancer than patients without receiving SGLT2 inhibitors. Conclusion The results demonstrated that patients with diabetes receiving SGLT2 inhibitors had a significantly lower risk of cancer. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Semaglutide Forum: Game Changer for Weight Loss
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top